Thrivent Financial For Lutherans Cara Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$4.89 - $12.27 $7,667 - $19,239	-1,568 Reduced 3.39%	44,731 $220,000
Q4 2022 Feb 08, 2023	SELL	$8.88 - $12.77 $3,125 - $4,495	-352 Reduced 0.75%	46,299 $497,000
Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $41,669 - $63,515	5,057 Added 12.16%	46,651 $437,000
Q2 2022 Aug 16, 2022	BUY	$7.45 - $13.84 $55,942 - $103,924	7,509 Added 22.03%	41,594 $380,000
Q1 2022 May 13, 2022	SELL	$9.94 - $12.65 $2,822 - $3,592	-284 Reduced 0.83%	34,085 $414,000
Q4 2021 Feb 16, 2022	BUY	$11.99 - $18.14 $4,304 - $6,512	359 Added 1.06%	34,369 $419,000
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $13,617 - $18,934	-1,179 Reduced 3.35%	34,010 $525,000
Q2 2021 Aug 19, 2021	BUY	$12.38 - $29.19 $435,639 - $1.03 Million	35,189 New	35,189 $502,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.